 BidaskClub downgraded shares of Crinetics Pharmaceuticals NASDAQ:CRNX from a hold rating to a sell rating in a research note issued to investors on Wednesday, BidAskClub reports. CRNX has been the subject of a number of other research reports. HC Wainwright reiterated a buy rating and issued a 30.00 price target down previously from 35.00 on ... 